TYRA Tyra Biosciences, Inc.

QT27

Latest market price

21.33

+0.26+1.23%

Overview Short InterestFilings

TYRAQT27Tyra Biosciences, Inc.·NASDAQ

Overview Short InterestFilings

21.33+1.23%

Earnings

Up 1.2% — Earnings due 2026-11-04 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

QURE-7.49%$22.97 RARE+1.24%$16.30 NUVB-3.57%$4.59 TRAX-0.07%$45.05 NTLA-6.50%$11.66 ABSI-12.94%$9.69 URGN+5.01%$34.36 MAZE-3.53%$30.37

Snapshot

Index	—	P/E	—	EPS (ttm)	-2.40	Insider Own	—	Shs Outstand	59.66M	Perf Week	4.46%

Market Cap	1.27B	Forward P/E	—	EPS next Y	-2.80	Insider Trans	20.30%	Shs Float	44.33M	Perf Month	4.41%

Enterprise Value	923.61M	PEG	—	EPS next Q	-0.67			Short Float	21.42%	Perf Quarter	-34.43%

Income	-149.00M	P/S	—	EPS this Y	—			Short Ratio	11.14	Perf Half Y	-39.30%

Sales	0.00	P/B	3.59	EPS next Y	—	ROA	-38.75%	Short Interest	9.50M	Perf YTD	-18.87%

Book/sh	5.93	P/C	3.59	EPS next 5Y	—	ROE	-46.39%	52W High	40.65 -47.53%	Perf Year	36.03%

Cash/sh	5.93	P/FCF	—	EPS past 3/5Y	—	ROIC	-44.78%	52W Low	13.35 59.78%	Perf 3Y	93.73%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	5.23% 4.63%	Perf 5Y	5.54%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	1.12	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	14.91	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	50.77	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	14.91	EPS Q/Q	-46.81%	SMA20	5.53%	Beta	0.64	Target Price	43.40

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	—	SMA50	-5.53%	Rel Volume	0.61	Prev Close	21.07

Employees	87	LT Debt/Eq	0.01	Earnings	Nov 04	SMA200	-28.51%	Avg Volume	878.46K	Price	21.33

IPO Date	Sep 15, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.17% —	Net Debt/EBITDA	—	Volume	534,387	Change	1.23%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-06-26	Reiterated	Raymond James		$33 → $50
Sep-22-26	Reiterated	HC Wainwright & Co.	Buy	$45 → $29
Sep-22-26	Reiterated	Oppenheimer	Outperform	$50 → $40
Sep-08-26	Reiterated	Piper Sandler	Overweight	$42 → $56
Aug-05-26	Reiterated	Jefferies	Buy	$44 → $42
Apr-14-26	Initiated	Guggenheim	Buy	$54
Feb-17-26	Reiterated	HC Wainwright & Co.	Buy	$30 → $45
Feb-13-26	Reiterated	Wedbush	Outperform	$37 → $53
Feb-03-26	Reiterated	Oppenheimer	Outperform	$36 → $50
Jan-27-26	Initiated	Barclays	Overweight	$59

Latest News· Times ET

Oct-31-26

Oct-31-2605:14PM

Tyra Biosciences (TYRA) Stock Looks Rich Against Its Book ValueYahoo

Oct-22-26

Oct-22-2604:05AM

12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga

Oct-17-26

Oct-17-2603:11AM

Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book ValueYahoo

Oct-15-26

Oct-15-2610:00AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAprnewswire.com

Oct-14-26

Oct-14-2610:36AM

Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weekszacks.com

Oct-13-26

Oct-13-2605:48PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAglobenewswire.com

Oct-06-26

Oct-06-2604:50PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAglobenewswire.com

Oct-01-26

Oct-01-2604:26PM

Raymond James Updates Healthcare Top Picks for OctoberYahoo

Sep-29-26

Sep-29-2605:33PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAglobenewswire.com

Sep-25-26

Sep-25-2603:17AM

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89defenseworld.net

Sep-22-26

Sep-22-2609:10AM

Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40Benzinga

Sep-17-26

Sep-17-2610:00AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAprnewswire.com

Sep-16-26

Sep-16-2604:07PM

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?Yahoo

Sep-15-26

Sep-15-2605:32PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAglobenewswire.com

Sep-14-26

Sep-14-2606:45AM

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrantsprnewswire.com

Company

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	0	0	0	0	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—	—	—
Gross Profit	0	0	0	0	—	—	—	—
Selling, General and Administrative Excl. Other	34	30	24	17	—	—	—	—
Research and Development	125	103	80	63	—	—	—	—
Other Operating Expense	2	0	0	0	—	—	—	—
Operating Income	-161	-133	-104	-80	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	12	13	18	11	—	—	—	—
Net Income Before Taxes	-149	-120	-86	-69	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—
Consolidated Net Income	-149	-120	-86	-69	—	—	—	—
Net Income From Continuing Operations	-149	-120	-86	-69	—	—	—	—
Net Income	-149	-120	-86	-69	—	—	—	—
EPS (Recurring)	-2.40	-2.01	-1.51	-1.62	—	—	—	—
EPS (Basic, Before Extraordinaries)	-2.40	-2.01	-1.51	-1.62	—	—	—	—
EPS (Diluted)	-2.40	-2.01	-1.51	-1.62	—	—	—	—
EBITDA	-148	-119	-86	-69	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—
Shares Outstanding	66	60	57	43	—	—	—	—
Market Capitalization	1,408	1,577	792	596	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director, 10% Owner	Sep 15 '26	Buy	0.00	9,078,529	9,079	11,616,986	Sep 17
Verjee Rehan	Director	Sep 09 '26	Buy	20.58	972	20,000	972	Sep 11
KAPLAN GILLA	Director	Mar 26 '26	Option Exercise	2.25	106,344	239,274	81,403	Mar 27
KAPLAN GILLA	Director	Mar 25 '26	Option Exercise	2.25	14,295	32,164	42,526	Mar 27
KAPLAN GILLA	Director	Mar 25 '26	Sale	36.97	14,295	528,506	28,231	Mar 27
Bensen Daniel	Chief Discovery Officer	Feb 12 '26	Sale	32.87	8,000	262,965	146,981	Feb 13
Bensen Daniel	Chief Discovery Officer	Jan 12 '26	Sale	28.52	8,000	228,185	154,981	Jan 20
MORE ROBERT J	Director	Dec 19 '25	Sale	25.00	10,000	250,000	3,823,425	Dec 19
Bensen Daniel	Chief Discovery Officer	Dec 12 '25	Sale	22.64	8,000	181,159	162,981	Dec 16
MORE ROBERT J	Director	Nov 21 '25	Sale	20.25	246,871	5,000,026	3,833,425	Nov 25
Bensen Daniel	Chief Operating Officer	Nov 19 '25	Sale	16.32	49,956	815,297	170,981	Nov 19
Bensen Daniel	Chief Operating Officer	Nov 18 '25	Sale	16.07	75,633	1,215,627	220,937	Nov 19
Bensen Daniel	Chief Operating Officer	Nov 17 '25	Sale	16.18	20,072	324,798	296,570	Nov 17
Bensen Daniel	Chief Operating Officer	Nov 14 '25	Sale	16.02	110,228	1,765,489	316,642	Nov 17
Bensen Daniel	Chief Operating Officer	Nov 13 '25	Sale	16.00	1,111	17,780	426,870	Nov 17

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.